ArticleEuropean journal of human genetics : EJHG2026
Uncovering apparent incomplete penetrance of TSC1/TSC2 variants: Insights from multiple population cohorts and implications for newborn screening.
Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tuberous sclerosis complex (TSC) is a genetic multisystem disorder regarded as having near-complete penetrance, a view largely derived from clinically ascertained cohorts. As genomic newborn screening is piloted internationally, robust estimates of penetrance and expressivity in unselected populations are urgently needed. We analysed genome sequencing data from >900,000 adults in UK Biobank (UKB) and the All of Us Research Program (AoU), representing multiple genetic ancestries, to identify individuals carrying high-confidence ACMG/AMP (likely) pathogenic TSC1/TSC2 variants. Electronic health records and self-reported data were interrogated for TSC-related phenotypes, including diagnostic codes, and evidence of epilepsy, chronic kidney disease and other hamartomas. We identified 61 adults with (likely) pathogenic TSC1/TSC2 variants and phenotype data available. Only 20/61 (33%) had a recorded diagnosis of TSC and a further 8/61 (13%) had at least one TSC phenotype; 33/61 (54%) had no recorded TSC diagnosis, manifestations or suggestive medication history, despite median age ≥55 years (UKB ≥ 75 years) with extensive longitudinal healthcare data. Apparent reduced penetrance was observed for TSC1 in both cohorts (46.6% UKB, 46.1% AoU), consistent with previously reported milder phenotypes associated with this gene. Apparent TSC2 penetrance was also incomplete (27.8% UKB, 66.7% AoU, p = 0.038, not significant after Bonferroni correction). Borderline significant apparent penetrance differences between UKB and AoU were not explained by gene, variant class, or ClinVar designation, but may reflect healthy volunteer bias in UKB. Overall, these findings challenge the assumption of near-complete penetrance for (likely) pathogenic TSC1/TSC2 variants and have important implications for genomic newborn screening, variant interpretation and counselling of asymptomatic carriers.
Identifiers
42151584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.